866-997-4948(US-Canada Toll Free)

United States Biopsy Market, Volume & Forecast by Segments (Breast, Prostate, Lung, Liver & Thyroid) & Companies

Published By :

Renub Research

Published Date : Feb 2018

Category :

In Vitro Diagnostics

No. of Pages : 108 Pages

Renub Research report titled “United States Biopsy Market, Volume & Forecast by Segments (Breast, Prostate, Lung, Liver and Thyroid), Companies (C. R. Bard, Inc.,  Becton, Dickinson and Company, B. Braun Melsungen AG, Cardinal Health, Inc., Olympus Corporation, FUJIFILM Holdings Corporation, Medtronic plc., Hologic, Inc)” provides a complete analysis of the United States Biopsy Market and Volume.

United States Biopsy Market will cross US$ 17 Billion by the year 2024 owing to the rising prevalence of cancer in the region. According to the World Health Organization, cancer cases are expected to surge 57% worldwide in the next 20 years. Biopsies are most often done to look for cancer; a biopsy is a sample of tissue taken from the body in order to examine it more closely. Further, growing patient awareness and the advancement in the biopsy techniques are also expected to fuel future growth of biopsy market in United States.

The World Cancer Report, produced by the WHO's specialized cancer agency and released on World Cancer Day, predicts new cancer cases will rise from an estimated 14 million annually in 2012 to 22 million within two decades. Over the same period, cancer deaths are predicted to rise from 8.2 million a year to 13 million.

By Segment – United States Biopsy Market and Volume 

On segment basis, Breast cancer biopsies accounts for the highest share in the United States Biopsy Market for the year 2017. While, in terms of Volume, Breast cancer biopsy has second highest share. Further, the report also covers the market aspects of Liver, Lung and Thyroid cancer biopsies. The Unites States Biopsy Market and Volume will experience a major growth during the forecast period owing to the increasing number of biopsy procedures and rising demand for minimally invasive procedures

All the 8 companies studied in the report have been studied from 4 points 

  • Overview
  • Business Strategy    
  • Merger & Acquisition    
  • Financial Insight

This 108 page report with 28 Figures and 2 Tables provides a complete analysis of the key Growth Drivers and Challenges, market, and their projections for the upcoming years.

Segments Covered in the Report:

  • Breast Cancer Biopsy
  • Prostate Cancer Biopsy
  • Lung Cancer Biopsy
  • Liver Cancer Biopsy
  • Thyroid Cancer Biopsy

Key Companies Covered in the Report: 

  • C. R. Bard, Inc.
  • Becton, Dickinson and Company
  • B. Braun Melsungen AG
  • Cardinal Health, Inc.
  • Olympus Corporation
  • FUJIFILM Holdings Corporation
  • Medtronic plc.
  • Hologic, Inc

United States – Biopsy Testing Market – Overview

United States Biopsy Test Market was more than US$ 15 Billion in 2014 and future seems to be much brighter. In the United States Biopsy Test Market, Breast Cancer is the most popular segment in 2014. Thyroid cancer stands at the last spot, but it is the most rapidly increasing type of cancer in the United States. However if we make the analysis from the Volume point then Prostate Cancer is the most popular segment. Increasing United States prevalence of cancer, geriatric population and increasing demand for minimally invasive procedures are expected to drive market growth during the forecast period.  

Renub Research report titled “United States – Biopsy Testing Market & Volume Analysis to 2020” provides a comprehensive assessment of the fast–evolving, high–growth of Biopsy Market. This 53 page report with 28 Figures and 1 Table analyses the United States Biopsy Test Market and Volume by 5 Top Cancer Segment, driving factors and challenges for Biopsy market.

The United States Biopsy Market has been analyzed from two view points

  • United States Biopy Test Market & Forecast (2008 – 2020)
  • United States Biopy Test Volume & Forecast (2008 – 2020)

The Top 5 Cancer Segments covered are:

  1. Breast Cancer
  2. Prostate Cancer
  3. Liver Cancer
  4. Lung Cancer
  5. Thyroid Cancer

Table of Content

1. Executive Summary

2. United States Biopsy Market & Volume (2008 – 2024)
2.1 Market & Forecast
2.2 Volume & Forecast

3. Share Analysis – United States Biopsy (2008 – 2024)
3.1 Market Share & Forecast
3.2 Volume Share & Forecast

4. Segments Analysis – United States Biopsy Market (2008 – 2024)
4.1 Prostate Cancer Biopsy
4.1.1 Market & Forecast
4.1.2 Volume & Forecast
4.2 Breast Cancer Biopsy
4.2.1 Market & Forecast
4.2.2 Volume & Forecast
4.3 Lung Cancer Biopsy
4.3.1 Market & Forecast
4.3.2 Volume & Forecast
4.4 Liver Cancer Biopsy
4.4.1 Market & Forecast
4.4.2 Volume & Forecast
4.5 Thyroid Cancer Biopsy
4.5.1 Market & Forecast
4.5.2 Volume & Forecast

5. Growth Drivers (Due to data confidentiality, growth drivers have not been disclosed in this table of contents)
5.1 Point No. 1
5.2 Point No. 2
5.3 Point No. 3
5.3.1 Point A
5.3.2 Point B
5.3.3 Point C
5.3.4 Point D
5.3.5 Point E

6. Challenges (Due to data confidentiality, challenges have not been disclosed in this table of contents)
6.1 Point No. 1
6.2 Point No. 2

7. Company Analysis
7.1 C. R. Bard, Inc.
7.1.1 Overview
7.1.2 Merger & Acquisition
7.1.3 Financial Insight
7.2 Becton, Dickinson and Company
7.2.1 Overview
7.2.2 Business Strategy
7.2.3 Merger & Acquisition
7.2.4 Financial Insight
7.3 B. Braun Melsungen AG
7.3.1 Overview
7.3.2 Business Strategy
7.3.3 Merger & Acquisition
7.3.4 Financial Insight
7.4 Cardinal Health, Inc.
7.4.1 Overview
7.4.2 Business Strategy
7.4.3 Merger & Acquisition
7.4.4 Financial Insight
7.5 Olympus Corporation
7.5.1 Overview
7.5.2 Business Strategy
7.5.3 Merger & Acquisition
7.5.4 Financial Insight
7.6 Boston Scientific Corporation
7.6.1 Overview
7.6.2 Business Strategy
7.6.3 Merger & Acquisition
7.6.4 Financial Insight
7.7 Medtronic plc
7.7.1 Overview
7.7.2 Business Strategy
7.7.3 Merger & Acquisition
7.7.4 Financial Insight
7.8 Hologic, Inc.
7.8.1 Overview
7.8.2 Business Strategy
7.8.3 Merger & Acquisition
7.8.4 Financial Insight

List of Table

Table 6?1: New Bundled Codes for Breast Biopsy With Image Guidance
Table 6?2: Breast Biopsy - Final Medicare Physician Fee Schedule, 2015

List of Chart

Figure 2?1: United States - Biopsy Market (Million US$), 2008 -2017
Figure 2?2: United States – Forecast for Biopsy Market (Million US$), 2018 -2024
Figure 2?3: United States - Biopsy Volume (Thousand), 2008 -2017
Figure 2?4: United States – Forecast for Biopsy Volume (Thousand), 2018 - 2024
Figure 3?1: United States - Biopsy Test Market Share (Percent), 2008 – 2017
Figure 3?2: United States – Forecast for Biopsy Test Market Share (Percent), 2018 – 2024
Figure 3?3: United States - Biopsy Volume Share (Percent), 2008 – 2017
Figure 3?4: United States – Forecast for Biopsy Volume Share (Percent), 2018 – 2024
Figure 4?1: United States - Prostate Cancer Biopsy Market (Million US$), 2008 -2017
Figure 4?2: United States – Forecast for Prostate Cancer Biopsy Market (Million US$), 2018 -2024
Figure 4?3: United States - Prostate Cancer Biopsy Volume (Thousand), 2008 -2017
Figure 4?4: United States – Forecast for Prostate Cancer Biopsy Volume (Thousand), 2018 -2024
Figure 4?5: United States - Breast Cancer Biopsy Market (Million US$), 2008 -2017
Figure 4?6: United States – Forecast for Breast Cancer Biopsy Market (Million US$), 2018 -2024
Figure 4?7: United States - Breast Cancer Biopsy Volume (Thousand), 2008 -2017
Figure 4?8: United States – Forecast for Breast Cancer Biopsy Volume (Thousand), 2018 -2024
Figure 4?9: United States - Lung Cancer Biopsy Market (Million US$), 2008 -2017
Figure 4?10: United States – Forecast for Lung Cancer Biopsy Market (Million US$), 2018 -2024
Figure 4?11: United States - Lung Cancer Biopsy Volume (Thousand), 2008 -2017
Figure 4?12: United States – Forecast for Lung Cancer Biopsy Volume (Thousand), 2018 -2024
Figure 4?13: United States - Liver Cancer Biopsy Market (Million US$), 2008 -2017
Figure 4?14: United States – Forecast for Liver Cancer Biopsy Market (Million US$), 2018 -2024
Figure 4?15: United States - Liver Cancer Biopsy Volume (Thousand), 2008 -2017
Figure 4?16: United States – Forecast for Liver Cancer Biopsy Volume (Thousand), 2018 -2024
Figure 4?17: United States - Thyroid Cancer Biopsy Market (Million US$), 2008 -2017
Figure 4?18: United States – Forecast for Thyroid Cancer Biopsy Market (Million US$), 2018 -2024
Figure 4?19: United States - Thyroid Cancer Biopsy Volume (Thousand), 2008 -2017
Figure 4?20: United States – Forecast for Thyroid Cancer Biopsy Volume (Thousand), 2018 -2024
Figure 7?1: C. R. Bard – Financial Insights (Million US$), 2010 – 2017
Figure 7?2: Becton, Dickinson and Company – Financial Insights (Million US$), 2010 – 2017
Figure 7?3: Becton, Dickinson and Company – Financial Insights Forecasted (Million US$), 2018 – 2024
Figure 7?4: B. Braun Melsungen AG – Financial Insights (Million US$), 2011 – 2017
Figure 7?5: B. Braun Melsungen AG - Financial Insights Forecasted (Million US$), 2018 – 2024
Figure 7?6: Cardinal Health, Inc. – Financial Insights (Billion US$), 2010 – 2017
Figure 7?7: Cardinal Health, Inc. – Financial Insights Forecasted (Billion US$), 2018 – 2024
Figure 7?8: Olympus Corporation – Financial Insights (Million US$), 2012 – 2017
Figure 7?9: Olympus Corporation – Financial Insights Forecasted (Million US$), 2018 – 2024
Figure 7?10: Boston Scientific Corporation – Financial Insights (Billion US$), 2012 – 2017
Figure 7?11: Boston Scientific Corporation – Financial Insights Forecasted (Billion US$), 2018 – 2024
Figure 7?12: Medtronic plc – Financial Insights (Million US$), 2010 – 2017
Figure 7?13: Medtronic plc – Financial Insights Forecasted (Million US$), 2018 – 2024
Figure 7?14: Hologic Inc. – Financial Insights (Billion US$), 2013 – 2017
Figure 7?15: Hologic Inc. – Financial Insights Forecast (Million US$), 2018 – 2024

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *